Recent Advances in the Management of MRD+ ALL
Controversies and Recommendations for the Treatment of ALL and Lymphoblastic Lymphoma in 2023
By
Indy Hematology Review
FEATURING
Wendy Stock
By
Indy Hematology Review
FEATURING
Wendy Stock
Login to view comments.
Click here to Login
Recent Advances in the Management of MRD+ ALL